Kids' obesity may change how acid reflux drugs work

NCT ID NCT04248335

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how obesity affects the way children's bodies process common acid reflux medications like lansoprazole and pantoprazole. Researchers gave a single dose of these drugs to 76 children aged 6-21, both with and without obesity, and measured how long the drugs stayed in their blood. The goal was to understand if obesity changes drug clearance and dosing needs, which could lead to safer, more effective use in kids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lansoprazole, Pantoprazole, Midazolam
What this could lead to
If successful, this could help doctors prescribe more accurate doses of acid reflux drugs for children with obesity.
What could go wrong
This is a small, completed study focused on measuring drug levels, not testing a new treatment. Results may not apply to all children or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Mercy Kansas City

    Kansas City, Missouri, 64108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.